Chronic Obstructive Pulmonary Disease – China In-Depth – COPD – China In-Depth
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death in China and, thus, a major public health concern. We expect the Chinese COPD therapy market to experience robust growth over the 2020-2030 forecast period, driven by the uptake of several recently launched, novel, premium-priced therapies—including LAMA/LABA FDCs and ICS/LAMA/LABA FDCs—and their inclusion in China’s National Reimbursement Drug List. Given the diverse late-phase pipeline, we expect more novel therapies to launch during the forecast period, further driving market growth. Additionally, in view of the ongoing reforms in China’s regulatory and access and reimbursement landscape, multinational companies will be encouraged to enter this market.
QUESTIONS ANSWERED
- How large is China’s drug-treatable COPD population, and how will drug-treatment rates change during the forecast period?
- Which are the most commercially relevant drugs in China’s COPD market and why? What are interviewed experts’ insights into current treatment options?
- What are the market access considerations for key therapies in the COPD pipeline in China? What sales could they secure in COPD? What are interviewed experts’ opinions of key emerging therapies?
- What are the key drivers and constraints in the China COPD therapy market, and how will the market evolve over the forecast period?
PRODUCT DESCRIPTION
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Release Date
December 2021
Geographies
China
Primary Research
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 50 pulmonologists.
Epidemiology
Diagnosed prevalence of COPD in urban versus rural China; clinically relevant and commercially relevant drug-treatable populations
Forecast
10-year, annualized, drug-level sales and patient share of key COPD therapies through 2030, based on primary and secondary market research to formulate bottom-up assumptions
Emerging Therapies
Phase III/PR: 9 drugs; Phase II: 3 drugs; coverage of select preclinical and Phase I products.
Akash Saini, M.Sc., Ph.D., is the manager of the China In-Depth team at Clarivate. In this role, he leads the efforts to create syndicated landscape and forecast content on various therapy areas for the Chinese market. Previously, he was an assistant manager at BioXcel, where he led consulting projects based on in-silico drug discovery and identification of drug repurposing and in-licensing opportunities. Dr. Saini received his Ph.D. in biochemistry and biotechnology from the International Centre for Genetic Engineering and Biotechnology in New Delhi and conducted postdoctoral research at the University of Massachusetts Medical School. He earned his M.Sc. in biotechnology from Jawaharlal Nehru University in India.